Notice
Recent Posts
Recent Comments
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 |
Tags
- OTCBB
- LOTTE
- Investment
- nda
- Bank
- case study
- LOI
- private equity
- Malaysia
- acquisition
- China
- Japan Tobacco
- securities
- Merger
- Korea M&A
- PEF
- Letter of intent
- hong kong
- taiwan
- CA
- sk
- capital gate
- China Construction Bank
- Confidential Agreement
- Korea
- M&A
- Japan
- cgi korea
- Acquistion
- buyout
Archives
- Today
- Total
Korea M&A Corporation
GS’ acquisition of Hugel to change domestic BTX, bio markets
As the GS consortium is certain to acquire Korea's botulinum toxin (BTX) developer, Hugel, industry watchers are paying keen attention to how the acquisition would change the company and the domestic BTX and bio markets. The four-party private equity fund formed by the GS Group, also participated in by IMM Investment, China's CBC Group, and the United Arab Emirates (UAE) Mubadala Investment Comp..
News/M&A
2021. 8. 23. 10:23